Literature DB >> 1683288

A68930: a potent agonist selective for the dopamine D1 receptor.

M P DeNinno1, R Schoenleber, R MacKenzie, D R Britton, K E Asin, C Briggs, J M Trugman, M Ackerman, L Artman, L Bednarz.   

Abstract

A68930, (1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman HCl, is a potent (EC50 = 2.5 nM), partial (intrinsic activity = 66% of dopamine) agonist in the fish retina dopamine-sensitive adenylate cyclase model of the D1 dopamine receptor. In the rat caudate-putamen model of the D1 dopamine receptor, A68930 is a potent (EC50 = 2.1 nM) full agonist. In contrast, A68930 is a much weaker (EC50 = 3920 nM) full agonist in a biochemical model of the dopamine D2 receptor. The orientation of the 3-phenyl substituent in the molecule is critical for the affinity and selectivity of the molecule towards the dopamine D1 receptor. A68930 also displays weak alpha 2-agonist activity but the molecule is virtually inactive at the alpha 1- and beta-adrenoceptors. When tested in rats bearing a unilateral 6-OHDA lesion of the nigro-neostriatal neurons, A68930 elicits prolonged (greater than 20 h) contralateral turning that is antagonized by dopamine D1 receptor selective doses of SCH 23390 but not by D2 receptor selective doses of haloperidol. In this lesioned rat model, A68930 increases 2-deoxyglucose accumulation in the lesioned substantia nigra, pars reticulata. When tested in normal rats, A68930 elicits hyperactivity and, at higher doses, produces a forelimb clonus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683288     DOI: 10.1016/0014-2999(91)90459-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  A68930 is a potent, full agonist at dopamine1 (D1) receptors in renal epithelial LLC-PK1 cells.

Authors:  A Grenader; D P Healy
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

Review 2.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

3.  Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors.

Authors:  Jessica P Ryman-Rasmussen; Adam Griffith; Scott Oloff; Nagarajan Vaidehi; Justin T Brown; William A Goddard; Richard B Mailman
Journal:  Neuropharmacology       Date:  2006-10-24       Impact factor: 5.250

4.  Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase.

Authors:  A M Deveney; J L Waddington
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 5.  Brain dopamine receptors: 20 years of progress.

Authors:  J W Kebabian
Journal:  Neurochem Res       Date:  1993-01       Impact factor: 3.996

6.  Biphasic locomotor effects of the dopamine D1 agonist SKF 38393 and their attenuation in non-habituated mice.

Authors:  E Tirelli; P Terry
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.

Authors:  A M Deveney; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

8.  Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling.

Authors:  Gerard J O'Sullivan; Mark Dunleavy; Kerstin Hakansson; Mario Clementi; Anthony Kinsella; David T Croke; John Drago; Allen A Fienberg; Paul Greengard; David R Sibley; Gilberto Fisone; David C Henshall; John L Waddington
Journal:  Neuropharmacology       Date:  2008-02-21       Impact factor: 5.250

9.  The effects of clozapine on behavioural responses to the selective 'D1-like' dopamine receptor agonist, A 68930, and to the selective 'D2-like' agonist, RU 24213.

Authors:  S A Daly; J L Waddington
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

Review 10.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.